TY - JOUR
T1 - Conformationally-restricted arginine analogues as alternative substrates and inhibitors of nitric oxide synthases
AU - Lee, Younghee
AU - Marletta, Michael A.
AU - Martasek, Pavel
AU - Roman, Linda J.
AU - Masters, Bettie Sue Siler
AU - Silverman, Richard B.
N1 - Funding Information:
The authors are grateful to the National Institutes of Health for financial support of this research to R. B. S. (GM49725), M.A.M. (CA50414) and B.S.S.M. (GM52419) and to the Robert A. Welch Foundation (AQ-1192) for financial support to B.S.S.M.
PY - 1999/6
Y1 - 1999/6
N2 - Conformationally restricted arginine analogues (1-5) were synthesized and found to be alternative substrates or inhibitors of the three isozymes of nitric oxide synthase (NOS). A comparison of k(cat)/K(m) values shows that (E)-3,4-didehydro-d,l-arginine (1) is a much better substrate than the corresponding (Z)-isomer (2) and 3-guanidino-d,l-phenylglycine (3), although none is as good a substrate as is arginine; 5-keto-d,l-arginine (4) is not a substrate, but is an inhibitor of the three isozymes. Therefore, it appears that arginine binds to all of the NOS isozymes in an extended (E-like) conformation. None of the compounds exhibits time-dependent inhibition of NOS, but they are competitive reversible inhibitors. Based on the earlier report that N(ω)-propyl-l-arginine is a highly selective nNOS inhibitor (Zhang, H. Q.; Fast, W.; Marletta, M.; Martasek, P.; Silverman, R. B. J. Med. Chem. 1997, 40, 3869), (E)-N(ω)-propyl-3,4-didehydro-d,l-arginine (5) was synthesized, but it was shown to be weakly potent and only a mildly selective inhibitor of NOS. Imposing conformational rigidity on an arginine backbone does not appear to be a favorable approach for selective NOS inhibition. Copyright (C) 1999 Elsevier Science Ltd.
AB - Conformationally restricted arginine analogues (1-5) were synthesized and found to be alternative substrates or inhibitors of the three isozymes of nitric oxide synthase (NOS). A comparison of k(cat)/K(m) values shows that (E)-3,4-didehydro-d,l-arginine (1) is a much better substrate than the corresponding (Z)-isomer (2) and 3-guanidino-d,l-phenylglycine (3), although none is as good a substrate as is arginine; 5-keto-d,l-arginine (4) is not a substrate, but is an inhibitor of the three isozymes. Therefore, it appears that arginine binds to all of the NOS isozymes in an extended (E-like) conformation. None of the compounds exhibits time-dependent inhibition of NOS, but they are competitive reversible inhibitors. Based on the earlier report that N(ω)-propyl-l-arginine is a highly selective nNOS inhibitor (Zhang, H. Q.; Fast, W.; Marletta, M.; Martasek, P.; Silverman, R. B. J. Med. Chem. 1997, 40, 3869), (E)-N(ω)-propyl-3,4-didehydro-d,l-arginine (5) was synthesized, but it was shown to be weakly potent and only a mildly selective inhibitor of NOS. Imposing conformational rigidity on an arginine backbone does not appear to be a favorable approach for selective NOS inhibition. Copyright (C) 1999 Elsevier Science Ltd.
KW - Arginine analogues
KW - Conformationally-restricted
KW - Enzyme inhibition
KW - Nitric oxide synthase
UR - http://www.scopus.com/inward/record.url?scp=0033011043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033011043&partnerID=8YFLogxK
U2 - 10.1016/S0968-0896(99)00029-2
DO - 10.1016/S0968-0896(99)00029-2
M3 - Article
C2 - 10428379
AN - SCOPUS:0033011043
SN - 0968-0896
VL - 7
SP - 1097
EP - 1104
JO - Bioorganic and Medicinal Chemistry
JF - Bioorganic and Medicinal Chemistry
IS - 6
ER -